ContraFect Corp. is a clinical-stage biotechnology company. It focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. The company scientific and clinical strategy focuses on the use of combination therapies. ContraFect was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
